Does Aggressive Surgery Save Lives? A New Era in Breast Cancer in Young Patients

Surgical Choice in Young Women With High-Risk Breast Cancer: Mastectomy and Breast-Conserving Approaches in Light of I-SPY2 Results

The I-SPY2 Study: Patient Profile and Surgical Distribution

This large-scale analysis, led by Dr. Jennifer Tseng of the Breast Surgery Department at City of Hope Orange County, examined retrospective and prospective data from a total of 1.737 patients enrolled in the I-SPY2 clinical trial with clinically stage II or III high-risk breast cancer and high MammaPrint scores. Before surgery, all patients received modern neoadjuvant systemic treatments standardized according to their molecular subtypes.

To clearly assess how surgical decision-making relates to age, the cohort was divided into two main groups: patients aged 45 and younger, the young cohort, and those older than 45. Anthropometric and clinical matching found similar tumor biology, stages and axillary surgery approaches in both groups. However, a significant divergence was identified in the choice of surgical technique.

During the study follow-up, averaging 5 years, surgical practices were observed to change over time, with a gradual increase in the trend toward breast-conserving surgery among young women as well. Nevertheless, the historically and culturally pronounced preference for radical surgery among younger patients retained its weight in the data.

Long-Term Sequelae of Extensive Surgery and the Need for De-escalation

Surgical de-escalation in breast cancer, reducing the extent of treatment without reducing its effectiveness, is more than a cosmetic concern: it is directly a component of quality of life and survival. The physical and psychosocial burdens of aggressive mastectomies and accompanying reconstruction processes in young women can have much more dramatic consequences than in the older population.

Permanent loss of sensation in the chest wall, postmastectomy pain syndrome (PMPS), impaired body image, sexual dysfunction, anxiety and substantial financial toxicity from reconstruction costs and lost work are frequently reported after mastectomy. I-SPY2 data provide a scientific basis showing that these aggressive procedures, which offer no additional survival advantage, unnecessarily put young women's quality of life at risk.

Methodological Assessments and Decision-Making

Although the I-SPY2 results are very strong, certain methodological limits and patient-specific variables must be considered when integrating them into clinical practice. Surgical decision-making should rely on a multicomponent algorithm, rather than only on the patient's age or tumor stage.

This article was compiled in accordance with professional medical publishing principles using current peer-reviewed clinical research data presented at international oncology congresses and platform protocol documents available as of 2026. It is solely for informational purposes and does not constitute an individual medical diagnosis or treatment protocol. In high-risk breast cancer, the local surgical approach should be planned on a fully individualized basis by a multidisciplinary tumor board consisting of a surgeon, medical oncologist and radiation oncologist, according to the patient's genetic mutation profile, tumor subtype, clinical/pathological response to neoadjuvant treatment and chest wall anatomy.